SMS Pharmaceuticals · NSE: SMSPHARMA · BSE: 532815
Q4 FY23 results · Jan–Mar 2023
SMS Pharmaceuticals reported revenue from operations of ₹149.43 crore (up 145.3% from Q4 FY22) and net profit of ₹6.22 crore (up 0.7% from Q4 FY22) for Q4 FY23 (Jan–Mar 2023), on a consolidated basis.
| Item | Q4 FY23 | Q4 FY22 | YoY | Q3 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 149.43 | 60.92 | +145.3% | 148.80 | +0.4% |
| Other income | 1.26 | 0.43 | +194.7% | 2.21 | −43.3% |
| Total income | 150.68 | 61.35 | +145.6% | 151.02 | −0.2% |
| Profit before share of associates & JVs and tax | 10.63 | (16.33) | Turned profit | 6.67 | +59.5% |
| Share of profit/(loss) of associates & JVs | (1.85) | (2.73) | (1.51) | ||
| Net profit for the period | 6.22 | 6.17 | +0.7% | 3.76 | +65.2% |
| EPS, basic (₹) | 0.73 | 0.73 | +0.0% | 0.44 | +65.9% |
| Net margin (%) | 4.2 | 10.1 | 2.5 |
This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.
| Item | Q4 FY23 | Q4 FY22 | YoY | Q3 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 149.43 | 60.92 | +145.3% | 148.80 | +0.4% |
| Other income | 1.26 | 0.43 | +194.7% | 2.21 | −43.3% |
| Total income | 150.68 | 61.35 | +145.6% | 151.02 | −0.2% |
| Profit before tax | 10.64 | (16.17) | Turned profit | 6.42 | +65.8% |
| Net profit for the period | 8.07 | 9.06 | −10.9% | 5.03 | +60.6% |
| EPS, basic (₹) | 0.95 | 1.07 | −11.2% | 0.59 | +61.0% |
| Net margin (%) | 5.4 | 14.9 | 3.4 |
Consolidated
- Filed with BSE
- 24 May 2023, 20:25 IST
- Board meeting
- 24 May 2023
- Period
- 01 Jan 2023 to 31 Mar 2023
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 24 May 2023, 20:25 IST
- Board meeting
- 24 May 2023
- Period
- 01 Jan 2023 to 31 Mar 2023
- Review status
- Audited
- Source
- XBRL filing on BSE